WuXi Biologics breaks ground on CRDMO Center in Singapore

The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network

WuXi XDC partners with IntoCell to accelerate ADC discovery and development

IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate

WuXi XDC and Boostimmune sign MoU for integrated services

Boostimmune will have access to WuXi XDC's fully integrated one-stop bioconjugate platform

GeneQuantum and WuXi XDC enter into strategic cooperation to empower innovative bioconjugates development

WuXi STA launches parenteral formulation manufacturing line at Wuxi

This is the second line opened this year for parenteral drug product clinical and commercial manufacturing, with an annual capacity of 10 million units

WuXi STA opens a new sterile lipid nanoparticle formulation facility

This new facility integrates multi-channel chip, micro-mixer system, and complex preparation system into a multi-channel micro-mixer core LNP manufacturing platform

WuXi STA breaks ground for second manufacturing facility in US

This biopharmaceutical facility is one most significant private sector investment ever in the Middletown region

WuXi STA opens a new large scale continuous manufacturing plant at Changzhou site

WuXi STA opens a new large scale continuous manufacturing plant

WuXi AppTec plans to build a new site in Singapore

Better serving global partners and advancing healthcare innovation

WuXi XDC and AbTis sign MoU for manufacturing of antibody drug conjugates

AbTis will have access to WuXi XDC's integrated services for linker and payload manufacturing